Crinetics Pharmaceuticals, Inc.
CRNX
Jodie situation report
Crinetics Pharmaceuticals, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 8 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
- At least 9 of 13 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as BMRN begins moving with the group.
Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.
Who this business touches
The relationships behind CRNX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
LLYEli Lilly and CompanypartnerFeb 26, 2026 ▾
“In July 2024, Radionetics formed a strategic partnership with Eli Lilly and Company (“Lilly”), receiving a $ 140.0 million upfront payment and granting Lilly the exclusive right to acquire Radionetics for $ 1.0 billion.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CRNX is currently a Early Follower in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.